CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PRUSOGLIPTIN TABLETS OBTAINS MARKETING APPROVAL GRANTED BY NMPA

The board of directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that Prusogliptin Tablets (brand name: Shanzeping (善澤平)) (the "**Product**"), a Class 1 new chemical drug developed by the Group, has obtained marketing approval granted by the National Medical Products Administration (NMPA) of the People's Republic of China.

The Product is a novel oral dipeptidyl peptidase-IV (DPP-4) inhibitor which is highly selective and strongly inhibitory towards DPP-4. By inhibiting DPP-4, the Product elevates the level of endogenous active glucagon-like peptide-1 (GLP-1) and thus enhances the sensitivity of β-cells and α-cells towards glucose, leading to increased glucose-stimulated insulin secretion and enhanced inhibitory effect of glucose towards glucagon secretion, thereby lowering blood glucose levels. The Product is indicated for the improvement of glycemic control in adults with type 2 diabetes, including monotherapy and combination therapy when metformin hydrochloride alone does not provide adequate glycemic control.

The results of the two pivotal phase III clinical trials supporting the approval of the Product (a phase III trial of prusogliptin tablets as monotherapy and a phase III trial of prusogliptin tablets in combination with metformin hydrochloride) have demonstrated that the Product has a long-lasting glucose-lowering effect and is not prone to inducing hypoglycemia and weight gain. In addition, the Product has a low incidence of adverse reactions and drug interactions. No dosage adjustment is required when the Product is used in patients with mild to moderate renal impairment.

Type 2 diabetes is the most common type of diabetes in adults. According to the International Diabetes Federation, there were approximately 540 million adults (aged 20–79 years) with diabetes worldwide in 2021, with approximately 140 million in China, and the number of adults with diabetes in China was estimated to increase to 174 million by 2045.

The approval of the Product will provide a new treatment option for patients with type 2 diabetes and further enrich the Group's product portfolio in metabolism.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 13 January 2025

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.